IL5 and asthma: Previous studies have shown that PI3K inhibitors suppress pathological features associated with asthma, including chemokine secretion by activated eosinophils, increased levels of IL-5 and IL-13 in the bronchi, and eosinophil infiltration in lung tissue [15].